Abstract | BACKGROUND: METHODS: RESULTS: PYD, DPYD and NTX showed a significant decrease lasting four weeks (p<0.01, <0.01 and <0.001, respectively). OHPRO and ICTP did not change significantly. The NTX decline was greater than that of PYD and DPYD (maximum percent decrease: -71.3, -23.1 and -28.2, respectively). Bone formation markers and serum calcium did not change significantly. Serum PTH showed a rapid initial increase followed by a slow decrease (p<0.001). DPYD and NTX patterns did not correlate with changes in bone pain. As observed in the last 17 cases, the maximum osteolysis inhibition after pamidronate occurred on the fourth day after drug infusion. Serum IL-6 levels showed a short-lived decrease preceded by a transient rise on the fourth day. CONCLUSIONS:
|
Authors | A Berruti, L Dogliotti, M Tucci, R Tarabuzzi, S Guercio, M Torta, M Tampellini, A Dovio, M Poggio, R M Scarpa, A Angeli |
Journal | The International journal of biological markers
(Int J Biol Markers)
2002 Oct-Dec
Vol. 17
Issue 4
Pg. 244-52
ISSN: 0393-6155 [Print] United States |
PMID | 12521128
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Collagen Type I
- Diphosphonates
- Interleukin-6
- Parathyroid Hormone
- Peptide Fragments
- Peptides
- Procollagen
- collagen type I trimeric cross-linked peptide
- Pamidronate
- Calcium
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(therapeutic use)
- Bone Neoplasms
(secondary)
- Bone Resorption
(metabolism)
- Calcium
(blood)
- Collagen Type I
- Diphosphonates
(pharmacology, therapeutic use)
- Humans
- Interleukin-6
(biosynthesis)
- Male
- Middle Aged
- Pamidronate
- Parathyroid Hormone
(blood)
- Peptide Fragments
(blood)
- Peptides
- Procollagen
(blood)
- Prostatic Neoplasms
(drug therapy, metabolism, pathology)
|